Avicanna Reports Q3 2024
Revenue of $6.3 million and $18.8 million for the three- and nine-month period ending September 30, 2024, representing a 0.34 ...
Eye on the prize: $15.9m boost for Opthea’s vision impairment therapy
Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax incentive from ...